The rate of new or worsening immune-related adverse events was no higher than previously reported.
The median cancer-specific survival was 56.5 months.
The median time to first onset of key adverse reactions was within 5 months of starting lenvatinib-pembrolizumab.
Nearly half of non-clear cell renal cell carcinoma samples were classified as proliferative.
Patients with smaller target lesions at baseline were more likely to be long-term survivors.
Iodine concentration and Hounsfield units were associated with treatment response and survival.
The seroconversion rate was 92%.
It was previously unknown whether the survival benefits seen with lenvatinib plus pembrolizumab persisted in the long term.
Researchers determined that few patients with poor risk aRCC were receiving first-line avelumab plus axitinib.
The monthly incremental cost per survivor relative to sunitinib for nivolumab plus ipilimumab decreased over time from $90,035 for 12 months to $18,881 for 48 months.
The investigators aimed to understand how oncologists decide between IO/IO and IO/TKI treatment options via survey.
Patients with BAP1-mutant ccRCC have very poor prognosis and comprise 10% to 15% of ccRCC cases.
Researchers hypothesized that adverse radiologic and pathologic T3 features are predictive of worse outcomes in small renal masses.
Investigators presented the longest phase 3 follow up reported for a checkpoint inhibitor combination therapy in aRCC.
Investigators assessed the association between DFS and OS in patients with newly diagnosed, completely resected, intermediate-high or high-risk RCC post-nephrectomy.
A total of 651 patients with clear cell aRCC were randomly assigned to receive nivolumab plus cabozantinib or sunitinib.
A retrospective physician-administered chart review evaluated AEs and management strategies used in United States clinical practice among adult patients with aRCC.
No major difference in outcome was observed in a retrospective analysis of patients with mRCC and bone metastasis treated with IO with and without prior radiation.